Phenylephrine ready-to-use injection (Biorphen®)

Biorphen®, the first and only FDA-approved ready-to-use formulation of phenylephrine for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Prior to the FDA approval of Biorphen®, phenylephrine injection was only approved and available as a highly concentrated formulation that required hospitals to manually dilute the concentrate prior to administration, or purchase ready-to-use formulations from 503B compounding pharmacies. See below comparison between previously approved concentrated formulation of Phenylephrine injection (Vazuclep®) and Biorphen®.